CSIMarket Company Name, Ticker, Industry, else..
 
Metsera Inc   (NASDAQ: MTSR)
 

Metsera Inc's Suppliers Performance

MTSR's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
MTSR Costs vs Sales of Suppliers Growth

• More on MTSR Suppliers






Metsera Inc's Comment on Supply Chain


Amneal is the designated supplier responsible for providing an agreed percentage of annual commercial drug substance and drug product requirements, including up to 100 million cartridge-based injectable drug product units per year and drug substance up to the maximum annual capacity of a new manufacturing facility in India. Amneal is also tasked with constructing new manufacturing facilities in India for injectable peptide drug products, with a portion dedicated to a minimum annual capacity of 100 million units for the company. The company is obligated to pay up to $100 million over four years to support the construction and may receive up to $100 million in rebates based on units manufactured. The supply price consists of a fixed price plus a markup and an earn-out based on gross profit. In the event of supply failure, the company may source from alternate suppliers and receive credits from Amneal. Amneal is required to prioritize orders and maintain safety stock. The supply agreement remains in effect until the seventh anniversary of the first commercial sale, with options to renew. Termination conditions include material breach, insolvency, or change of control events affecting Metsera or Amneal.

Metsera Inc's Comment on Supply Chain


Amneal is the designated supplier responsible for providing an agreed percentage of annual commercial drug substance and drug product requirements, including up to 100 million cartridge-based injectable drug product units per year and drug substance up to the maximum annual capacity of a new manufacturing facility in India. Amneal is also tasked with constructing new manufacturing facilities in India for injectable peptide drug products, with a portion dedicated to a minimum annual capacity of 100 million units for the company. The company is obligated to pay up to $100 million over four years to support the construction and may receive up to $100 million in rebates based on units manufactured. The supply price consists of a fixed price plus a markup and an earn-out based on gross profit. In the event of supply failure, the company may source from alternate suppliers and receive credits from Amneal. Amneal is required to prioritize orders and maintain safety stock. The supply agreement remains in effect until the seventh anniversary of the first commercial sale, with options to renew. Termination conditions include material breach, insolvency, or change of control events affecting Metsera or Amneal.







MTSR's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Metsera Inc 7,404.64 0.00 0.00 -
SUBTOTAL 0.00 0.00 0.00 -


Sources: Metsera Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Metsera Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.